Polaryx Therapeutics, INC

Polaryx Therapeutics, Inc. reported the immediate resignation of its Chief Medical Officer, Lisa Bollinger, MD, on July 19, 2026.

Polaryx Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026, with a record date of July 27, 2026.

Polaryx Therapeutics has closed a $10 million private placement to fund its upcoming SOTERIA Phase 2 basket trial.

CEO Alex Keun Mo Yang acquired 88,453 shares of Polaryx Therapeutics through Mstone Partners Healthcare in a private placement.

Polaryx Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for September 10, 2026, to elect directors and ratify auditor appointment.